---
canonical_name: Kanna
alternate_names: Sceletium tortuosum, Mesembryanthemum tortuosum, Kougoed, Channa, Zembrin
canonical_topic: Kanna for Health & Longevity
short_topic_lc: kanna
creation_date: 2026-0825-1904
creator_ai_fullname: Opus 5
ep_keywords: Nootropics, Adaptogens
---

# Kanna for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5

**Also known as:** Sceletium tortuosum, Mesembryanthemum tortuosum, Kougoed, Channa, Zembrin

  
## Motivation

<!-- Author's note: this Motivation section was written last, after every other section of this review had been completed, so that it reflects the full scope of the evidence assembled below. -->

Kanna is a small succulent plant from the dry interior of southern Africa. For centuries the fermented plant was chewed to lift mood, settle nerves, and blunt hunger and thirst on long journeys. Modern interest centres on a family of plant compounds that act on the brain chemistry governing mood and calm, and on a standardised extract now sold worldwide as a capsule.

Written descriptions of the plant reach back to Dutch traders in the seventeenth century, and it remains one of southern Africa's most valued traditional plants. Over the past two decades it has moved from a regional remedy to a global supplement, marketed for stress, focus, and social ease, and online interest in it has grown quickly. Nearly all of the human research so far has been carried out in healthy volunteers rather than in people seeking treatment.

This review examines what the human and laboratory evidence shows about kanna: how it appears to work, which benefits have actually been measured and on what strength of evidence, which harms and interactions have been reported, and how it is dosed, sourced, and monitored.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

This section lists high-level overviews of kanna from expert commentators and from qualifying academic literature.

<!-- Author's search statement: on 16 August 2026 real-time searches were run for "kanna", "Sceletium tortuosum", "Mesembryanthemum tortuosum", "kougoed", and "Zembrin" across the open web and on the six priority expert platforms individually (foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com, lifespan.io), using both external web search and each site's own search function. Only hubermanlab.com returned substantive content naming the intervention. Academic candidates were screened to exclude systematic reviews, meta-analyses, encyclopedias, database entries, forums, and mainstream media. -->

* [The Science of Gratitude & How to Build a Gratitude Practice](https://www.hubermanlab.com/episode/the-science-of-gratitude-and-how-to-build-a-gratitude-practice) - Andrew Huberman

  A neurobiology podcast episode whose final segment covers kanna and its standardised extract directly, framing the compound's serotonin-related actions alongside prosocial and gratitude circuitry.

* [Mesembryanthemum tortuosum and Zembrin: Mixed Evidence from In vivo Animal and Clinical Studies on their Antidepressant and Anxiolytic Effects](https://pubmed.ncbi.nlm.nih.gov/41771298/) - de Jong et al., 2026

  The most current critical appraisal of every published animal and human study, and the clearest statement of where the evidence is thin: small samples and healthy rather than clinical populations.

* [Sceletium for Managing Anxiety, Depression and Cognitive Impairment: A Traditional Herbal Medicine in Modern-Day Regulatory Systems](https://pubmed.ncbi.nlm.nih.gov/33588735/) - Brendler et al., 2021

  Traces how kanna is regulated across major markets and why an African botanical faces steep barriers to product approval, useful context for judging the commercial forces shaping its research.

* [A Chewable Cure "Kanna": Biological and Pharmaceutical Properties of Sceletium tortuosum](https://pubmed.ncbi.nlm.nih.gov/33924742/) - Manganyi et al., 2021

  A broad narrative overview linking traditional San and Khoikhoi use to the modern pharmacology, covering antimicrobial, antioxidant, anti-inflammatory, and mood-related activities in one place.

* [Mesembrine alkaloids: Review of their occurrence, chemistry, and pharmacology](https://pubmed.ncbi.nlm.nih.gov/27939420/) - Krstenansky, 2017

  The reference account of the individual alkaloids, explaining which molecule contributes which pharmacological action and where the chemistry remains incompletely characterised.

Of the six priority expert platforms, only Huberman Lab was found to discuss kanna by name; searches of the other five returned no content on this plant, so no item from them could be included.

  
## Grokipedia

<!-- Author's search statement: grokipedia.com was searched directly with the browser tool on 16 August 2026 for "Sceletium tortuosum" and "kanna". The search returned 19 results, the first of which is a dedicated primary article at /page/Sceletium_tortuosum. -->

* [Sceletium tortuosum](https://grokipedia.com/page/Sceletium_tortuosum)

  The dedicated article covers botany, distribution, traditional Khoikhoi and San use, alkaloid chemistry, and the modern commercial extract, providing a compact orientation before the primary literature.

  
## Examine

<!-- Author's search statement: examine.com was searched directly with the browser tool on 16 August 2026 for "kanna" and "Sceletium tortuosum". A dedicated supplement page exists at /supplements/kanna/, last updated 28 July 2025. -->

* [Kanna](https://examine.com/supplements/kanna/)

  Grades the outcome-level evidence, noting only 31 participants across two trials, and summarises the dosing range studied, an unusually blunt account of how little human data exists.

  
## ConsumerLab

<!-- Author's search statement: consumerlab.com was searched directly on 16 August 2026 for "kanna" and for "sceletium". Both queries returned "Sorry, we didn't find any results". No product review, clinical update, or answer covering this intervention exists on the site. -->

No ConsumerLab article, product review, or independent test report on kanna exists; the site has not covered this ingredient.

  
## Systematic Reviews

This section lists the systematic reviews indexed on PubMed that address kanna.

<!-- Author's search statement: PubMed was searched on 16 August 2026 using "(Sceletium tortuosum OR kanna OR mesembrine OR Zembrin OR Mesembryanthemum) AND (systematic review OR meta-analysis)", and again with the Systematic Review and Meta-Analysis publication-type filters applied. Exactly one indexed systematic review addresses this intervention; no meta-analysis exists. -->

* [Skeletons in the closet? Using a bibliometric lens to visualise phytochemical and pharmacological activities linked to Sceletium, a mood enhancer](https://pubmed.ncbi.nlm.nih.gov/38576783/) - Reddy et al., 2024

  Maps the entire Sceletium literature and identifies the gaps: almost no toxicology, few clinical studies, and minimal bioavailability data.

Kanna's central trade-off is mood benefit against serotonergic and product-quality harm. The one indexed systematic review covers the claimed benefit side; no systematic review or meta-analysis of kanna's harms, interactions, or safety exists, so the risk side of the trade-off is unrepresented in this section.

  
## Mechanism of Action

Kanna's activity comes from the mesembrine-type alkaloids (nitrogen-containing plant compounds) of *Sceletium tortuosum*, chiefly mesembrine, mesembrenone, mesembrenol, and mesembranol. In receptor screening of a standardised extract, the material blocked the serotonin transporter, or SERT (the protein that pulls the mood-related messenger serotonin back out of the synapse), at 4.3 µg/mL, and inhibited phosphodiesterase-4, or PDE4 (an enzyme that degrades the intracellular signalling molecule cyclic AMP), at 8.5 µg/mL (half-maximal inhibitory concentrations), with no effect on other phosphodiesterases ([Harvey et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21798331/)). That screening, like most of the human trial programme, was funded by the extract's manufacturer, HG&H Pharmaceuticals. Mesembrine drives the transporter effect; mesembrenone contributes both.

A competing mechanistic account exists. In astrocytes and hippocampal neurons, a mesembrine-rich extract raised vesicular monoamine transporter-2 expression while downregulating the serotonin transporter, arguing that monoamine *release* is the primary action and reuptake inhibition is secondary ([Coetzee et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26615766/)). Extracts from different wild chemotypes (populations with differing alkaloid mixes) raised noradrenaline and lowered GABA (gamma-aminobutyric acid, the brain's main calming messenger) in mice, implicating minor alkaloids beyond mesembrine ([Kaschula et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40374049/)).

Pharmacokinetics are poorly characterised. No human half-life has been published. In mice, intravenous alkaloids were quantifiable but oral plasma concentrations fell below detection, indicating poor oral bioavailability ([Manda et al., 2017](https://pubmed.ncbi.nlm.nih.gov/27526669/)). No tissue-distribution data exist; brain penetration is inferred from the central effects, not measured. Liver preparations O- and N-demethylate, hydroxylate, then glucuronidate or sulfate both alkaloids; the specific cytochrome enzymes have not been assigned ([Meyer et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25240931/)).

  
## Historical Context & Evolution

Kanna's original use was neither clinical nor cosmetic. San hunter-gatherers and Khoikhoi pastoralists chewed the fermented aerial parts to suppress thirst and hunger on long journeys, to relieve toothache and abdominal pain, and for social and spiritual gatherings. Dutch explorers documented the practice in 1685, and by the late eighteenth century the fermented product was a significant trade commodity in the Eastern Cape. Preparation mattered: crushing, bagging to ferment, then sun-drying converts mesembrine to delta-7-mesembrenone and reduces mesembrine content in the aerial parts from roughly 1.33% to 0.05%, while removing oxalates.

The pivot toward health optimisation came from the pharmacology. Once the alkaloids were shown to act on the serotonin transporter and on PDE4, the traditional mood claim acquired a plausible molecular basis, and a hydroethanolic extract standardised to 0.35–0.45% total alkaloids was developed for the supplement market ([Murbach et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25301237/)). That standardisation, and the manufacturer-funded trial programme behind it, is what moved kanna from ethnobotanical curiosity to a supplement with registry-listed clinical studies.

Scientific opinion is still moving rather than settled. The reuptake-inhibitor account was the consensus for a decade before the monoamine-release data challenged it; neither side has been retired, and the newer chemotype work suggests the active principle may not be a single molecule at all.

  
## Expected Benefits

<!-- Author's search statement: before writing this section, a dedicated search of the intervention's complete benefit profile was run on 16 August 2026 across PubMed (all 59 title/abstract-indexed records for Sceletium tortuosum, Mesembryanthemum tortuosum, and Zembrin), ClinicalTrials.gov, Examine.com, drugs.com, and general web search, to confirm no measured benefit has been omitted. -->

### High 🟩 🟩 🟩

No benefit of kanna currently reaches this evidence level. The entire human dataset consists of five small randomised trials, none exceeding 60 participants and none conducted in a clinical population; no meta-analysis exists.

### Medium 🟩 🟩

#### Acute Blunting of Situational Anxiety ⚠️ Conflicted

A single 25 mg dose lowered subjective anxiety before a simulated public-speaking task and altered the heart-rate trajectory across the stressor in healthy volunteers ([Reay et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32761980/)). A separate pharmaco-fMRI trial (fMRI is functional magnetic resonance imaging, which maps brain activity) found the same dose attenuated amygdala reactivity to fearful faces and reduced amygdala–hypothalamus coupling ([Terburg et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23903032/)). Evidence is conflicted: a companion multitasking study by the same group found no treatment effect at all.

**Magnitude:** Amygdala reactivity to fearful faces fell with a large effect size (partial η² = 0.33; η² is the share of the variation attributable to treatment), while the behavioural trial reports significance without an effect size; the anxiolytic direction holds only for acute, discrete stressors such as public speaking, not for sustained multitasking load.

#### Improved Cognitive Flexibility and Executive Function

Twenty-five milligrams once daily for three weeks improved cognitive set flexibility (p < 0.032; p estimates how likely a result is to be chance) and executive function (p < 0.022) versus placebo in a randomised, double-blind, placebo-controlled crossover trial in 21 healthy adults aged 45–65 ([Chiu et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25389443/)). The proposed mechanism is PDE4 inhibition raising cyclic AMP signalling. Only two of ten tested cognitive domains improved; memory, reaction speed, and attention did not, and the trial was investigator-described as proof-of-concept.

**Magnitude:** Two of ten cognitive domains improved significantly over placebo across three weeks, with large effect sizes (Cohen's d 1.47 for cognitive flexibility and 1.49 for executive function; Cohen's d expresses a difference in standard deviations), executive function showing a 24.0% change against 13.3% on placebo.

#### Faster Complex Reaction Under Cognitive Load

Eight days of 25 mg daily improved performance on reactive tasks requiring a decision (p < 0.001) in 60 recreationally trained adults aged 20–35, in a randomised placebo-controlled design ([Hoffman et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32740286/)). Simple reaction time, visual tracking, and total mood score were unchanged, so the signal is specific to tasks carrying a cognitive load rather than to raw speed. For an audience using the compound for work or training performance, this is the most directly applicable finding.

**Magnitude:** Significant gain confined to reactive agility with a decision component (p < 0.001) and one visual-stimulus response measure (p = 0.05); the trial reports no effect size for either.

### Low 🟩

#### Subjective Mood and Sleep Quality

Sleep-onset improvement reached significance on the sleep item of the Hamilton Depression Rating Scale (a clinician-rated depression questionnaire) in the 21-participant crossover trial, with positive mood change on the same scale ([Chiu et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25389443/)). Participants had no insomnia at baseline, so the ceiling was low.

**Magnitude:** The sleep-onset item fell from 0.76 to 0.43 across three weeks of treatment (p = 0.049), with no significant change on placebo (p = 0.606); no minutes-to-sleep figure was reported.

#### Appetite and Thirst Suppression ⚠️ Conflicted

The oldest traditional use — suppressing hunger and thirst on long journeys — is not supported by the trial data. The one trial that recorded these outcomes found the opposite direction ([Chiu et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25389443/)), so ethnobotanical report and controlled observation directly conflict.

**Magnitude:** Increased appetite in 10% and increased thirst in 10% of treated participants, the reverse of the traditional claim; no trial has measured suppression as a prespecified endpoint.

### Speculative 🟨

#### Anti-inflammatory and Cytoprotective Activity

Basis is in vitro only: extract raised interleukin-10 release and fully prevented endotoxin-driven loss of mitochondrial viability in human monocytes ([Bennett & Smith, 2018](https://pubmed.ncbi.nlm.nih.gov/29253615/)). No human inflammatory endpoint has been measured.

#### Neuroprotection in Parkinsonian Models

Basis is animal work only: extract restored motor function and reduced oxidative stress in reserpine-treated zebrafish larvae ([Lepule et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42451736/)). No human neurodegenerative endpoint exists.

#### Pain Relief

Basis is rodent and ethnobotanical only: isolated mesembrine raised hot-plate pain thresholds in rats without impairing coordination, matching the traditional use for toothache ([Loria et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24930358/)). No human pain endpoint exists.

  
## Benefit-Modifying Factors

* **Serotonin transporter genotype:** The short allele of 5-HTTLPR (a length variant in the serotonin transporter gene) lowers transporter production and predicts weaker response to reuptake-inhibiting agents; no kanna trial has genotyped participants, so this is extrapolated.

* **Demethylation capacity:** Both alkaloids are cleared by O- and N-demethylation; individuals with reduced activity in the relevant hepatic enzymes would plausibly retain higher plasma levels, but the specific cytochromes have not been assigned in the published metabolism work.

* **Baseline anxiety level:** Benefit was detectable only where a stressor produced measurable arousal. Participants with low baseline anxiety scores showed no signal, and no trial has enrolled anyone with a diagnosed anxiety disorder.

* **Baseline cognitive headroom:** The cognitive gains appeared in adults averaging 54.6 years, not in the 20–35 cohort, whose mood scores did not move. Existing performance appears to cap the measurable gain.

* **Sex:** Response by sex has never been analysed. The largest trial enrolled 48 men and 12 women without disaggregating results, so any sex difference in effect size remains entirely unmeasured.

* **Age:** Both the cognitive and mood signals came from the 45–65 cohort; the younger cohort showed only reaction-task changes. For adults at the older end, this is the more relevant evidence base.

* **Pre-existing depression or anxiety:** Every human trial excluded clinical populations. Whether benefit in healthy volunteers transfers to people with a diagnosis is untested, and the direction of transfer cannot be assumed.

  
## Potential Risks & Side Effects

<!-- Author's search statement: before writing this section, the complete side-effect profile was searched on 16 August 2026 using the drugs.com natural-products monograph for Sceletium tortuosum, WebMD, the Operation Supplement Safety entry, the published toxicology assessments, and all indexed PubMed records, to confirm no reported harm has been omitted. -->

### High 🟥 🟥 🟥

No risk of kanna reaches this evidence level. No serious adverse event has been attributed to the plant in any randomised trial, and no case report of severe harm has been published.

### Medium 🟥 🟥

#### Mild Treatment-Emergent Adverse Effects ⚠️ Conflicted

The three-week crossover trial recorded weight gain in 14% of treated participants and increased appetite, increased thirst, and fatigue in 10% each, plus headache, nausea, constipation, drowsiness, and difficulty concentrating at 5% ([Chiu et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25389443/)). Evidence is conflicted: across three months at 8 mg and 25 mg, headache, abdominal pain, and respiratory infection were all *more* frequent on placebo than on treatment, with no change in vital signs, electrocardiogram, or laboratory chemistry ([Nell et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23441963/)).

**Magnitude:** Highest single reported incidence is 14% for weight gain over three weeks; the longer three-month trial found no excess of any adverse event over placebo.

#### Wide Product Variability and Undeclared Constituents

Commercial kanna products are not chemically equivalent. Quantification across six retail products found hordenine (a stimulant amine not usually declared on labels) ranging from 0.027 to 1.071 mg per gram of plant material ([Appley et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34750996/)). Forensic screening separately confirmed the banned stimulant ephedrine as an undeclared adulterant in a commercial kanna sample ([Lesiak et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26821203/)). Wild chemotypes also differ sharply in alkaloid profile, producing different neurochemical effects in mice ([Kaschula et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40374049/)). Dose reproducibility across brands cannot be assumed.

**Magnitude:** Roughly 39-fold variation in hordenine content between commercial products (0.027 to 1.071 mg/g), plus confirmed ephedrine in at least one retail sample, with no corresponding label disclosure.

### Low 🟥

#### Motor Incoordination at Higher Doses

An extract fraction produced ataxia (loss of coordinated movement) on a rotating-rod test in rats, alongside its antidepressant-like effect, though isolated mesembrine relieved pain without ataxia and without signs of drug-seeking ([Loria et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24930358/)). Whether the effect appears at supplement doses in humans is untested.

**Magnitude:** Ataxia present in rats at extract-fraction doses; the study reports no dose threshold, and no human motor impairment has been documented at 25 mg.

#### Serotonergic Interaction Potential

The extract blocks the serotonin transporter potently and may also release monoamines ([Harvey et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21798331/)), the same pharmacology that drives serotonin syndrome (a dangerous excess of serotonin signalling) when reuptake inhibitors are combined. No published human case implicates kanna.

**Magnitude:** Not quantified in available studies. No controlled trial has co-administered kanna with a serotonergic drug, and no case series exists from which an incidence could be derived.

### Speculative 🟨

#### Adrenal Steroid Suppression

Basis is cell work only: extract inhibited cortisol, aldosterone, and testosterone production in adrenocortical cells ([Swart & Smith, 2016](https://pubmed.ncbi.nlm.nih.gov/26608706/)), apparently by blocking CYP17 (an enzyme that starts steroid hormone synthesis). No human hormone measurement exists.

#### Pro-inflammatory Response at Higher Doses

Basis is a single rodent study: extract raised interleukin-1β, C-reactive protein, and prostaglandin E2, which the investigator read as intolerance rather than benefit ([Smith, 2011](https://pubmed.ncbi.nlm.nih.gov/20816940/)). Direction contradicts the in vitro anti-inflammatory data.

  
## Risk-Modifying Factors

* **Demethylation and glucuronidation capacity:** Reduced hepatic conjugation would raise alkaloid exposure and plausibly shift mild effects toward intolerance; the responsible enzymes are unassigned, so no genotype test currently informs this.

* **Serotonin transporter genotype:** Carriers of low-expressing 5-HTTLPR variants who are already taking a reuptake inhibitor would face the largest theoretical additive serotonergic load, though no kanna-specific data exist.

* **Baseline serum sodium:** Reuptake-inhibiting agents can lower sodium. A baseline near the lower reference limit is the most plausible marker of susceptibility, particularly alongside diuretics.

* **Baseline blood pressure and heart rate:** Kanna altered the heart-rate response to laboratory stress. Established hypertension is the state in which an unmeasured cardiovascular effect would matter most.

* **Sex:** No trial has reported adverse events separately by sex, and women were a minority in every cohort, so any sex-specific risk signal is currently invisible in the data.

* **Age:** Older adults carry higher background risk of low sodium and of taking several serotonin-raising medications at once; the three-month safety trial enrolled general-population adults, not an elderly cohort.

* **Pre-existing psychiatric or cardiac disease:** All trials excluded these conditions. Anyone with bipolar disorder, an anxiety disorder under treatment, or arrhythmia falls entirely outside the tested population.

  
## Key Interactions & Contraindications

* **Selective serotonin reuptake inhibitors (a class of antidepressant, e.g. sertraline, escitalopram, fluoxetine):** Caution to absolute avoidance; additive serotonin transporter blockade with theoretical risk of serotonin syndrome. Mitigation: no concurrent use.

* **Serotonin–noradrenaline reuptake inhibitors (antidepressants that raise both serotonin and noradrenaline, e.g. venlafaxine, duloxetine):** Caution to avoidance; same additive mechanism plus added noradrenaline. Mitigation: no concurrent use; where antidepressant treatment is planned, kanna is stopped first.

* **Monoamine oxidase inhibitors (drugs blocking the enzyme that degrades monoamines, e.g. phenelzine, tranylcypromine, selegiline):** Absolute contraindication; blocked degradation plus increased release is the classic serotonin syndrome combination.

* **Other serotonergic prescription agents (tramadol, triptans such as sumatriptan, linezolid, lithium):** Caution; cumulative serotonergic burden. Mitigation: avoidance, or use only under prescriber supervision with symptom monitoring.

* **Over-the-counter dextromethorphan (in cough syrups such as Robitussin DM, Delsym):** Caution; dextromethorphan itself inhibits serotonin reuptake, and both are freely available. Mitigation: separated entirely during a cough illness.

* **Over-the-counter sedating antihistamines (diphenhydramine, doxylamine):** Caution; additive drowsiness reported with kanna at higher doses. Mitigation: no same-evening use.

* **Serotonergic supplements (5-hydroxytryptophan, L-Tryptophan, St. John's wort, S-adenosylmethionine):** Caution; each raises serotonin availability by a different route. Mitigation: no stacking, with at least a week between trials of each.

* **Calming supplements with additive effect (ashwagandha, L-Theanine, kava, valerian):** Caution; additive sedation and blunted alertness. Mitigation: one addition at a time; the recruiting stress trial excludes these outright.

* **Phosphodiesterase-4 inhibitor medications (roflumilast, apremilast):** Caution; kanna inhibits the same enzyme, so gastrointestinal and neuropsychiatric effects of those drugs may be amplified. Mitigation: monitoring for nausea and mood change.

* **Cannabis:** Caution; traditional accounts describe kanna intensifying cannabis intoxication, and the alkaloids interact with cannabinoid type 1 receptors. Mitigation: no concurrent use, particularly with concentrated extracts.

* **Alcohol:** Caution; additive sedation and impaired coordination given the ataxia seen in animal work. Mitigation: separation by several hours.

**Populations who should avoid Kanna:**

* Anyone taking a monoamine oxidase inhibitor, or within 14 days of stopping one
* Anyone taking a selective serotonin or serotonin–noradrenaline reuptake inhibitor
* Pregnant or breastfeeding individuals — no safety or efficacy data exist in either state
* Children and adolescents under 18 — no trial has enrolled anyone below 18
* People with bipolar disorder — untested, and serotonergic agents can precipitate mania
* People with a Patient Health Questionnaire-9 score above 9, or any suicidality item above 0 — the exclusion threshold used in the current recruiting trial
* People with uncontrolled hypertension (above 160/100 mmHg) or a known arrhythmia

  
## Risk Mitigation Strategies

* **Medication review before the first dose:** A full medication list screened for serotonergic agents is the first step; concurrent reuptake inhibitors or monoamine oxidase inhibitors are the single plausible route to serious harm with this compound.

* **Low starting dose:** Protocols open at 8 mg of standardised extract daily for one week before moving to 25 mg; 8 mg was carried through the three-month safety trial with no excess adverse events.

* **Daily dose capped at 25 mg of standardised extract:** No human trial has tested more. Higher doses move into the range where animal ataxia and euphoria-then-sedation were described.

* **Declared alkaloid specification:** A certificate of analysis stating 0.35–0.45% total alkaloids limits the roughly 39-fold between-product variability that otherwise makes dose meaningless.

* **Morning dosing:** Alertness and reaction effects were measured after morning dosing; evening use risks the difficulty-concentrating and drowsiness reported at 5% incidence interfering with sleep architecture.

* **Blood pressure and heart rate rechecked at four weeks:** A four-week recheck detects the cardiovascular drift that no trial has excluded, given the heart-rate changes observed under laboratory stress.

* **Continuous use limited to three months without reassessment:** Three months is the longest interval with published safety data; beyond it, tolerability is unstudied rather than established.

* **Inhaled and insufflated formats set aside:** Vaporised and snuffed products bypass first-pass metabolism entirely, delivering an unknown dose; every clinical trial used oral capsules.

  
## Therapeutic Protocol

* **Standard daily protocol:** 25 mg of a standardised hydroethanolic extract once daily by mouth, the dose used in every positive human trial and in the currently recruiting acute-stress study.

* **Low-dose alternative:** 8 mg once daily, carried through the three-month randomised safety trial; appropriate where tolerability is the priority over measured cognitive effect.

* **Acute situational protocol:** A single 25 mg dose taken 30 to 60 minutes before a discrete stressor, the design under which anxiety and amygdala effects were demonstrated.

* **Traditional preparation:** 50 to 200 mg of dried, fermented, milled aerial material chewed or taken as tincture or tea; potency is not comparable to standardised extract.

* **Competing approach — whole-plant chemotype:** Advocates of wild-harvested material argue minor alkaloids drive the effect; commercial standardisation deliberately narrows the alkaloid profile. Neither approach has been tested against the other in humans.

* **Origin of each approach:** The standardised extract was developed by HG&H Pharmaceuticals with Nigel Gericke as medical director; the chemotype argument comes from academic groups at Stellenbosch University.

* **Time of day:** Morning, with or without food. Alertness and reaction effects were measured in morning testing, and the 5% incidence of drowsiness argues against evening use.

* **Half-life:** No human half-life has been published. Mouse work found oral plasma levels below the limit of detection, so duration of action is inferred from effect timing, not pharmacokinetics.

* **Single versus split dosing:** All human trials used a single daily dose; splitting has never been studied, and Examine's monograph states optimal dosing frequency remains unknown.

* **Genetic considerations:** No pharmacogenetic testing informs dosing. Neither the metabolising cytochromes nor a 5-HTTLPR-stratified response has been characterised for this compound.

* **Sex-based dosing:** No sex-specific dose has been established; trials used identical doses in men and women without reporting outcomes separately.

* **Age considerations:** The 45–65 cohort showed cognitive benefit at 25 mg; for adults at the older end, the same dose is the only one studied, with no reduction protocol published.

* **Baseline biomarkers influencing response:** Higher baseline stress reactivity predicted a detectable effect; participants without measurable arousal showed none, so a low-anxiety baseline predicts a null result.

* **Pre-existing conditions:** Every protocol was run in healthy volunteers. No dosing guidance exists for depression, anxiety disorder, hypertension, or neurodegenerative disease.

  
## Discontinuation & Cycling

* **Intended duration:** Short-term rather than lifelong. The longest controlled exposure is three months, so open-ended daily use extends beyond any safety evidence.

* **Withdrawal effects:** None documented. Ethnobotanical accounts of chronic traditional use report no withdrawal syndrome on stopping, and no trial recorded discontinuation symptoms.

* **Tapering:** No taper protocol has been published or appears necessary given the absence of withdrawal reports; abrupt cessation was used at the end of every trial.

* **Cycling:** Not established. No study has compared continuous with intermittent dosing, and no tolerance has been demonstrated or excluded over three months.

* **Situational rather than continuous use:** The acute-stress evidence supports as-needed dosing before discrete stressors, the pattern under test in the currently recruiting crossover trial.

  
## Sourcing and Quality

* **Standardised extract specification:** The studied material is a hydroethanolic extract standardised to 0.35–0.45% total alkaloids, with mesembrenone plus mesembrenol at 60% or more and mesembrine below 20% of that total.

* **Third-party testing:** The relevant quality marker is an independent certificate of analysis quantifying individual alkaloids, not merely total plant weight; no major independent testing organisation currently reviews kanna products.

* **Hordenine and adulterant disclosure:** Whether hordenine has been quantified is rarely stated. Retail products varied roughly 39-fold in this undeclared stimulant amine, and forensic screening has found the banned stimulant ephedrine in a commercial sample.

* **Reputable suppliers:** The standardised extract is produced by HG&H Pharmaceuticals and distributed by PLT Health Solutions under the Zembrin brand; these are the same parties funding most of the clinical literature.

* **Avoid raw-powder equivalence claims:** The standardised extract is roughly a 2:1 concentrate, so 25 mg of extract approximates 50 mg of dried plant. Products claiming milligram equivalence to capsule doses are misleading.

* **Sustainability and provenance:** The plant is wild-harvested from a restricted range in South Africa and subject to bioprospecting permit requirements; documented cultivated or permitted supply chains are preferable to anonymous wild material.

  
## Practical Considerations

* **Time to effect:** Acute anxiety and brain-imaging effects appeared within 60 minutes of a single dose; cognitive flexibility changes required three weeks of daily use, and reaction-task changes eight days.

* **Common pitfall — assuming any product works:** Trials used one standardised extract. Generic kanna powder, resin, or "full-spectrum" concentrate has never been tested and is not interchangeable with the studied material.

* **Common pitfall — stacking with antidepressants:** Users treat a botanical as pharmacologically inert. Kanna's primary action is the same as a prescription reuptake inhibitor, making that combination the main avoidable hazard.

* **Common pitfall — expecting a mood lift in healthy users:** Total mood score did not move in the younger cohort. The measured effects are on stress reactivity and specific cognitive tasks, not on baseline happiness.

* **Regulatory status:** Sold in the United States as a dietary supplement ingredient; not approved by the Food and Drug Administration for any indication, not scheduled by the Drug Enforcement Administration, and listed by a United Nations body among plants of concern.

* **Cost and payer incentives:** Kanna is inexpensive but paid out of pocket, whereas generic reuptake inhibitors cost cents per dose and are reimbursed. Insurers and health systems therefore have no financial incentive to fund kanna research or guidelines.

  
## Interaction with Foundational Habits

* **Sleep:** Potentially direct and positive at night's edge — improved sleep onset reached significance on a depression-scale sleep item — but the same trial recorded drowsiness and difficulty concentrating in a minority. Morning dosing captures the alertness effects while avoiding daytime sedation; evening dosing is unstudied.

* **Nutrition:** Direct and unfavourable in one trial, where increased appetite affected 10% of participants and weight gain 14%, contradicting the traditional appetite-suppressant claim. No nutrient depletion is documented. Food does not appear to affect absorption, and no fasting requirement was imposed in any protocol.

* **Exercise:** Potentiating for decision-based reactive tasks, with reactive agility improving significantly after eight days in trained adults, but no effect on simple reaction time, visual tracking, or fatigue. No blunting of training adaptation has been examined. Practical use is pre-session dosing for skill-based rather than strength work.

* **Stress management:** Direct and complementary. The effect appeared specifically around acute, discrete stressors, with amygdala threat reactivity attenuated. That makes it an addition to breathing or exposure practices used before a defined event, not a substitute for them, and it did nothing under sustained multitasking load.

  
## Monitoring Protocol & Defining Success

A genuine baseline, rather than an impression, is what makes any later change interpretable. That baseline comprises a seated blood pressure and resting heart rate on two separate mornings, a basic metabolic panel that includes serum sodium, liver enzymes, and a self-rated anxiety score captured on the same instrument used later. A morning cortisol draw is a reasonable addition given the adrenal-cell findings, though no human hormone change has been demonstrated. Because the compound targets stress reactivity rather than a laboratory value, the subjective score is the primary measure and the bloodwork exists to catch harm, not to demonstrate benefit.

Ongoing monitoring repeats the anxiety score weekly for the first month, rechecks blood pressure and heart rate at four weeks, and repeats sodium and liver enzymes at three months, then every six to twelve months where use continues.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Seated blood pressure | Below 120/80 mmHg | Detects cardiovascular drift the trials did not exclude | Taken seated, after five minutes' rest, and averaged over two morning readings |
| Resting heart rate | 50–70 bpm | Heart-rate response under stress changed with treatment | Measured on waking, before dosing; a wearable trend is more informative than a single reading; the conventional range runs 60–100 bpm, so a "normal" result can still sit above the functional target |
| Serum sodium | 137–142 mmol/L | Serotonin reuptake inhibition can lower sodium (hyponatremia, a low blood-sodium state) | Part of a basic metabolic panel; fasting not required; the conventional reference range runs 135–145 mmol/L, wider at both ends than the functional target; highest relevance over 60 or on diuretics |
| ALT | 10–26 U/L (women), 10–30 U/L (men) | Screens for liver strain from concentrated botanical extracts | ALT is alanine aminotransferase, a liver enzyme; conventional upper limits run near 40 U/L, well above the functional target |
| AST | 10–26 U/L | Pairs with ALT to separate liver from muscle origin | AST is aspartate aminotransferase; conventional upper limits run near 40 U/L, well above the functional target; also elevated after hard training independent of liver status, so testing within 48 hours of heavy exercise is uninformative |
| Morning cortisol | 10–18 µg/dL at 08:00 | Kanna extract suppressed cortisol output in adrenal cell work | Drawn between 07:00 and 09:00 fasting, and paired with DHEA-S, the adrenal androgen dehydroepiandrosterone sulfate; conventional morning ranges span roughly 5–23 µg/dL, much wider at both ends than the functional target |
| GAD-7 anxiety score | Below 5 | Tracks the outcome the compound actually targets | GAD-7 is the seven-item Generalized Anxiety Disorder questionnaire; self-administered at the same time of day each week |
| Sleep-onset latency | Under 20 minutes | The one sleep measure that moved in a controlled trial | No population target is established for supplement response; the informative signal is change from the individual's own two-week pre-treatment baseline |

Qualitative markers matter more here than any single laboratory value, and belong in the record alongside the numbers:

* Subjective calm in the 60 to 90 minutes after a dose, rated before and after a known stressor
* Ease of switching between tasks, the specific cognitive domain that improved in trial conditions
* Reaction quality in decision-heavy activity such as sparring, driving, or team sport
* Sleep onset and morning grogginess, since drowsiness was a reported adverse effect
* Appetite direction, given that appetite rose rather than fell in the one trial that recorded it
* Absence of agitation, tremor, sweating, or racing pulse, which would signal excess serotonin signalling

  
## Emerging Research

* **Large decentralised acute-stress trial:** [NCT07511088](https://clinicaltrials.gov/study/NCT07511088) is randomising 250 healthy adults to 25 mg standardised extract or placebo in a triple-blinded crossover, rating anxiety at 30, 60, and 120 minutes after self-identified stress episodes. Sponsored by PLT Health Solutions, the extract's distributor.

* **Eight-week supplementation trial:** [NCT05471804](https://clinicaltrials.gov/study/NCT05471804) at Northumbria University planned 120 participants with subjective stress as primary outcome, extending exposure well beyond the three-week designs. Registry status is listed as unknown, and no results have been posted.

* **Completed safety and cognition study:** [NCT01805518](https://clinicaltrials.gov/study/NCT01805518) registered 20 middle-aged participants and produced the cognitive-flexibility finding published by [Chiu et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25389443/). Its small size is the clearest illustration of how thin the positive evidence base is.

* **Chemotype standardisation:** [Kaschula et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40374049/) showed wild chemotypes raise noradrenaline and lower GABA differently from the commercial extract. If confirmed, this would weaken the case that the standardised product captures the active principle.

* **Neuroinflammation and chronic stress:** [Gericke et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40643548/) found extract and isolated mesembrine reversed only some behavioural and neuro-inflammatory changes in chronically stressed rats, a partial result that could strengthen or narrow the antidepressant case depending on replication.

* **Toxicology gap:** [Niżnik & Jurowski, 2025](https://pubmed.ncbi.nlm.nih.gov/40651754/) had to predict mesembrine's toxicological endpoints computationally because no experimental human data exist. Adverse in silico findings would materially weaken the safety argument built on rodent studies.

* **Evidence quality reassessment:** [de Jong et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41771298/) concludes the clinical record is mixed, limited by small samples and clinically irrelevant populations, and calls for large trials in populations that actually have the conditions being treated.

  
## Conclusion

Kanna is a southern African succulent whose active plant compounds act on the same brain messenger system that common antidepressants target, and on an enzyme involved in the cell signalling behind learning and mood. The traditional record is long and consistent; the human research record is short and thin. A handful of small trials in healthy volunteers suggests a real but narrow set of effects: less anxiety before a single stressful event, better switching between mental tasks after a few weeks, and quicker responses on tasks that require a decision. Nothing supports a broad mood lift, and one of the oldest traditional claims, appetite suppression, ran the opposite way when it was actually measured.

Reported harms have been mild and mostly short-lived, and several months of daily use produced no excess of unwanted effects over placebo capsules. The genuine hazards lie elsewhere: combining kanna with prescribed antidepressants, and the large chemical differences between retail products, which make any stated dose unreliable.

The evidence base carries an unusual concentration of commercial interest. The standardised extract's manufacturer and distributor funded or co-authored most of the positive human studies, including the one now recruiting, and no independent group has replicated the cognitive findings. That does not make the results wrong, but it does mean the reassuring picture rests largely on parties who benefit from it, with almost no evidence at all on the harm side.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**